To the Editor Dr Morelli and colleagues1 reported that for patients with septic shock, open-label intravenous use of esmolol was associated with reductions in heart rates to target levels without increased adverse events compared with standard care. In sepsis, outcomes are associated with the burden of infecting pathogens, adherence to the guidelines of the SSC,2 and host immunity.
Lin G. Short-Acting β-Blocker Administration in Patients With Septic Shock. JAMA. 2014;311(7):737. doi:10.1001/jama.2014.312